NXTC Profile
NextCure Inc (NXTC) is a clinical-stage biopharmaceutical company that is developing immunomedicines to treat cancer and other immune-related diseases. The company is based in Beltsville, Maryland, and was founded in 2015.
NextCure's lead product candidate is NC318, which is being developed for the treatment of various types of cancer, including non-small cell lung cancer, ovarian cancer, and head and neck cancer. NC318 is designed to block the immune checkpoint protein known as Siglec-15, which is thought to play a role in suppressing the immune system's ability to fight cancer.
In addition to NC318, NextCure has several other product candidates in development, including NC410, which is being developed for the treatment of advanced solid tumors, and NC762, which is being developed for the treatment of autoimmune diseases.
NextCure has partnerships with several companies in the pharmaceutical industry, including Eli Lilly and Company, which has a license agreement with NextCure for the development and commercialization of NC318.
|
